Literature DB >> 21212088

Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.

Mervi Oikonen1, Mikko Laaksonen, Ville Aalto, Jorma Ilonen, Reijo Salonen, Juha-Pekka Erälinna, Martin Panelius, Aimo Salmi.   

Abstract

BACKGROUND: Multiple sclerosis (MS) relapses have been associated with viral and bacterial infection epidemics in MS patients who have not used interferon.
OBJECTIVES: We studied whether environmental viral infections in the general population can be associated with increased MS relapse occurrence using retrospective data from 1986 to 1995 when interferons were not yet available.
METHODS: Logistic regression modelling was used to compare retrospectively the monthly relapse occurrence from 407 MS patients in Turku University hospital archives and data on ten different specifically diagnosed viral infection epidemics in the general population of Southwestern Finland from 1986 to 1995. The outcome was the odds ratio (OR) of very high relapse occurrence versus low relapse occurrence, or moderate versus low relapse occurrence.
RESULTS: After a peak in diagnosed influenza A cases in the general population, the MS relapse occurrence was 6.5 times more likely to be very high (95% CI 1.8-24.0) and 7.1 times more likely to be moderately high (95% CI 1.5-33.2). An increase in MS relapse counts also followed Epstein-Barr virus (EBV) infections (OR 4.4, 95% CI 1.3-15.1), but we found no significant association with adenovirus infections and MS relapses. The MS relapse occurrence was lowest in the summer months July-August (Chi-square test, p<0.01).
CONCLUSIONS: Our findings suggest that influenza A and EBV viral infections in the general population are associated with a higher occurrence of exacerbations in MS patients, and thus environmental infection data should be included in epidemiological models on MS relapses.

Entities:  

Mesh:

Year:  2011        PMID: 21212088     DOI: 10.1177/1352458510394397

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  21 in total

1. 

Authors:  Norbert Wagner; Frauke Assmus; Gabriele Arendt; Erika Baum; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Dirk Föll; Edeltraut Garbe; Jane Hecht; Ulf Müller-Ladner; Tim Niehues; Klaus Überla; Sabine Vygen-Bonnet; Thomas Weinke; Miriam Wiese-Posselt; Michael Wojcinski; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

2.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 3.  Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.

Authors:  Juan Xiao; Rongbing Yang; Sangita Biswas; Yunhua Zhu; Xin Qin; Min Zhang; Lihong Zhai; Yi Luo; Xiaoming He; Chun Mao; Wenbin Deng
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

Review 4.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

Review 5.  Role of pathogens in multiple sclerosis.

Authors:  Jane E Libbey; Matthew F Cusick; Robert S Fujinami
Journal:  Int Rev Immunol       Date:  2013-11-22       Impact factor: 5.311

Review 6.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

7.  COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.

Authors:  Anat Achiron; Mark Dolev; Shay Menascu; Daniela-Noa Zohar; Sapir Dreyer-Alster; Shmuel Miron; Emanuel Shirbint; David Magalashvili; Shlomo Flechter; Uri Givon; Diana Guber; Yael Stern; Michael Polliack; Rina Falb; Michael Gurevich
Journal:  Mult Scler       Date:  2021-04-15       Impact factor: 6.312

8.  Multiple sclerosis: modulation of toll-like receptor (TLR) expression by interferon-β includes upregulation of TLR7 in plasmacytoid dendritic cells.

Authors:  Katja Derkow; Jakob M J Bauer; Michael Hecker; Brigitte K Paap; Madhan Thamilarasan; Dirk Koczan; Eckart Schott; Katrin Deuschle; Judith Bellmann-Strobl; Friedemann Paul; Uwe K Zettl; Klemens Ruprecht; Seija Lehnardt
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

9.  CNS-targeted autoimmunity leads to increased influenza mortality in mice.

Authors:  Justin D Glenn; Matthew D Smith; Pei Xue; Yee Chan-Li; Samuel Collins; Peter A Calabresi; Maureen R Horton; Katharine A Whartenby
Journal:  J Exp Med       Date:  2017-01-05       Impact factor: 14.307

Review 10.  Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Authors:  Patricia K Coyle; Anne Gocke; Megan Vignos; Scott D Newsome
Journal:  Adv Ther       Date:  2021-06-01       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.